ArticleCurrent topics in medicinal chemistry2022
Article in Current topics in medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Radionuclide theranostics: advances and clinical applications in lung cancer.Frontiers in oncology · 2026Review
- Synthesis, radiolabeling, and evaluation of aFrontiers in bioengineering and biotechnology · 2026Article
- The Predictive Value ofCurrent medical imaging · 2026Article
- FLAIR-based radiomics signature from brain-tumor interface for early prediction of response to EGFR-TKI therapy in NSCLC patients with brain metastasis.Frontiers in cell and developmental biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
With the development of epidermal growth factor receptor (EGFR)-based tyrosine kinase inhibitors (TKIs) and their applications in the clinic, non-small-cell lung cancer (NSCLC) treatment has entered a new era, and a great number of patients have benefited. However, there still exist other subgroups of patients who may not benefit from EGFR TKIs, although EGFR mutation is the main driving mutation that leads to NSCLC. To identify potential NSCLC responders for TKI therapy and to detect EGFR status in vivo, noninvasive technology, such as TKI PET imaging, has been developed in recent years, and a great number of tyrosine kinase-targeted PET tracers have been reported. The visualization and quantification of EGFR expression in vivo by PET would provide the most important information for personalizing NSCLC therapy and prediction of response in clinical. This article reviews the progress of small molecular tyrosine kinase-targeted PET tracers and their applications in preclinical experiments and clinical studies. The current limitations and future development of these tracers are also briefly discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.